The Readout

The Readout Meghana Keshavan

STAT Plus: A tough week for MDMA-assisted psychotherapy

The Readout Meghana Keshavan

STAT Plus: Why did Novo pull heart failure paperwork for Wegovy?

The Readout Meghana Keshavan

STAT Plus: Sarepta CEO: We’re ‘pretty brilliant’

The Readout Elaine Chen

STAT Plus: A new drug for glioma means a windfall for Agios

The Readout Elaine Chen

STAT Plus: The exclusive biotech stories you need to read

The Readout Meghana Keshavan

STAT Plus: FDA ad comm favors Zevra’s Niemann-Pick drug

The Readout Elaine Chen

STAT Plus: Moderna is still in a Covid hangover

The Readout Elaine Chen

STAT Plus: venBio raises $528 million for its fifth fund

The Readout Elaine Chen

STAT Plus: The debate over how long to use Alzheimer’s drugs

The Readout Elaine Chen

STAT Plus: Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?

The Readout Meghana Keshavan

STAT Plus: The biotech news you need from the weekend

The Readout Elaine Chen

STAT Plus: The worst for Dexcom may not be over

The Readout Meghana Keshavan

STAT Plus: A potential rival for Wegovy and Zepbound enters the fray

The Readout Elaine Chen

STAT Plus: Merck lays off workers amid rough pharma job market

The Readout Elaine Chen

STAT Plus: Contradictory coverage decisions in North Carolina

The Readout Meghana Keshavan

STAT Plus: Four health care and biotech updates to stay on top of this week

The Readout Meghana Keshavan

STAT Plus: Novo, Lilly shares sink due to concerns over competition

The Readout Elaine Chen

STAT Plus: The biotech news stories you need to know today

The Readout Elaine Chen

STAT Plus: It’s happy hour (for now) for Alnylam

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

The Readout Elaine Chen

STAT Plus: Exclusive: European VC Forbion hires Dyne CEO, expands in US

The Readout Elaine Chen

STAT Plus: Intellia says its CRISPR-based therapy can be redosed